Roblitinib (FGF401) is primarily investigated for its potential in cancer treatment, particularly targeting tumors with fibroblast growth factor receptor 4 (FGFR4) overexpression. It is being studied in clinical trials for its efficacy in treating hepatocellular carcinoma (HCC) and other solid tumors where FGFR4 signaling plays a critical role. The compound works by selectively inhibiting FGFR4, which helps in reducing tumor growth and progression. Its application is focused on patients who may not respond to conventional therapies, offering a targeted approach to manage specific cancer types.